三生制药(01530)于2026年10月14日发布公告，披露于香港联合交易所场内回购股份事宜。本次回购股份数为337,500股，约占此前公司已发行股本(不包括库存股份)的0.01%。回购价格为每股14.40港元，合计涉资约486万港元。
本次回购完成后，截至2026年10月14日，三生制药已发行股本(不包括库存股份)数量变更为2,513,207,578股，库存股份数目相应增至25,113,500股，总已发行股份数维持在2,538,321,078股。
据公告显示，三生制药此前于2026年6月25日获得股东大会通过的回购授权，回购股份的剩余额度仍可用于后续股份回购。公司同时表示，本次股份回购已遵守香港联合交易所有限公司证券上市规则及相关法律法规。
公告由公司秘书黎少娟签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.